Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

Peter C. Austin · Multivariate Behavioral Research · 2011 · 11.9K citations · Full text

Public Health, Biostatistics, Causal Inference +15

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Life Sciences, Immunology, Neurology +17

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

George A. Schumacher, Gilbert W. Beebe, Robert F. Kibler et al. · Annals of the New York Academy of Sciences · 1965 · 1.4K citations

Life Sciences, Neurology, Neuroscience +10

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Fred Lublin, David H. Miller, Mark S. Freedman et al. · The Lancet · 2016 · 449 citations · Full text

Medicine, Neurology, Pharmacotherapy +10